Nova in Silico

Executive Summary

Nova in Silico is a French biotechnology company leveraging AI and machine learning to transform drug discovery and clinical development. Founded in 2020 and headquartered in Paris, the company has developed 'jinkō,' a clinical trial simulation platform that integrates mechanistic disease models with virtual patient populations. This platform aims to predict drug efficacy and optimize trial design, potentially reducing the duration, cost, and risk of clinical development. By enabling more efficient and data-driven decisions, Nova in Silico addresses critical bottlenecks in the pharmaceutical industry, offering a path to accelerate the delivery of new therapies. Although the company is still in an early stage with no disclosed funding or valuation, its innovative approach and focus on in silico trials position it well within the growing AI-driven drug discovery landscape.

Upcoming Catalysts (preview)

• Q3 2026Announcement of partnership with a major pharmaceutical company40% success
• H2 2026Closing of Series A funding round50% success
• Q4 2026Publication of platform validation results in a peer-reviewed journal60% success